In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
News|Videos|June 30, 2026
10 Experts Predict the Future of CTCL Treatment
Fact checked by: Kevin Kunzmann
At the 6th World Congress of Cutaneous Lymphoma, a group of world-leading CTCL expert consider what the field will abandon in the next decade.
Advertisement
Advertisement
Progression may feel slower in rare disease fields such as cutaneous T-cell lymphoma (CTCL) —the dearth of patients mean fewer data to inform clinical investigation, which means a more stagnant pipeline.
Related to this article
A rituximab biosimilar has been approved by the FDA.
Neoadjuvant PD-1–based immunotherapy plus chemotherapy produced pCRs across three cohorts in resectable locally advanced HNSCC.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
Antibodies directed against TNFR2, a regulator in the tumor microenvironment that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
Dostarlimab monotherapy produced a 27% response rate in PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma
Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.
Advertisement
Advertisement